Biogen's US Alzheimer's drug may also come to Europe
An aging population means Aduhelm could also be approved in Europe, Senior Analyst Søren Løntoft Hansen says.
BY RITZAU, TRANSLATED BY CATHERINE BRETT
After being approved by the US Food and Drug Administration (FDA), there is a good chance that Biogen's Alzheimer's drug will also be approved in Europe, Sydbank Senior Analyst Søren Løntoft Hansen says.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen passes FDA test for Alzheimer's medicine
For subscribers
Fate of Biogen’s stock rides on Alzheimer’s drug decision
For subscribers
Lundbeck backs Trintellix with new data
For subscribers
